Fluorouracil
Showing 1 - 25 of 2,623
Vitiligo, Topical Fluorouracil, Effervescent Mixture Trial in Cairo (a new effervescent mixture 5-florouracil formula,
Not yet recruiting
- Vitiligo
- +2 more
- a new effervescent mixture 5-florouracil formula
- 5-Fluorouracil plain powder
-
Cairo, EgyptFacualty of Pharmacy, Al Azhar University
Sep 12, 2022
CIN 2/3, HIV Trial in Lilongwe (Intravaginal 5-Fluorouracil (5-FU))
Not yet recruiting
- CIN 2/3
- HIV Infections
- Intravaginal 5-Fluorouracil (5-FU)
-
Lilongwe, MalawiUNC Project, Kamuzu Central Hospital
Jul 7, 2022
Actinic Keratosis Trial in United States (Biopsy, Calcipotriene, Fluorouracil)
Not yet recruiting
- Actinic Keratosis
- Biopsy
- +2 more
-
Tucson, Arizona
- +3 more
Jan 25, 2023
Oral Leukoplakia Trial in San Francisco (5-fluorouracil)
Not yet recruiting
- Oral Leukoplakia
-
San Francisco, CaliforniaUniversity of California, San Francisco
Aug 15, 2022
Superficial Basal Cell Carcinoma, Squamous Cell Carcinoma in Situ Trial in Boston, Quincy (Combination cream of 5-fluorouracil
Not yet recruiting
- Superficial Basal Cell Carcinoma
- Squamous Cell Carcinoma in Situ
- Combination cream of 5-fluorouracil and calcipotriene
- 5-fluorouracil cream
-
Boston, Massachusetts
- +1 more
Jul 29, 2022
Actinic Keratosis, Organ or Tissue Transplant; Complications Trial in Cleveland (5-Fluorouracil)
Terminated
- Actinic Keratosis
- Organ or Tissue Transplant; Complications
-
Cleveland, OhioCleveland Clinic
Mar 5, 2022
Vitiligo Trial in Qina (Latanoprost 0.005% Ophthalmic Solution, 5Fluorouracil)
Active, not recruiting
- Vitiligo
- Latanoprost 0.005% Ophthalmic Solution
- 5Fluorouracil
-
Qinā, Qena Governorate, EgyptSouth Valley University
Aug 22, 2022
Actinic Keratoses Trial in United States (Test Product (A): Fluorouracil Cream, 5% topical cream, Reference Product (B):
Recruiting
- Actinic Keratoses
- Test Product (A): Fluorouracil Cream, 5% topical cream
- +2 more
-
Bakersfield, California
- +6 more
Apr 22, 2022
Microvascular Function in Patients Undergoing 5-Fluorouracil
Recruiting
- Gastrointestinal Cancer
- +4 more
- Arterial blood pressure
- +3 more
-
Manhattan, KansasLafene Health Center
Mar 30, 2022
Scar Keloid Trial in Dharan Bazar (5-Fluorouracil)
Completed
- Scar Keloid
-
Dharān Bāzār, Province No. 1, NepalB.P. Koirala Institute of Health Sciences
Mar 30, 2022
Keloid Scar Trial in New York (Fractional erbium:YAG-assisted drug delivery of 5-fluorouracil, Fractional erbium:YAG-assisted
Recruiting
- Keloid Scar
- Fractional erbium:YAG-assisted drug delivery of 5-fluorouracil
- Fractional erbium:YAG-assisted drug delivery of triamcinolone acetonide
-
New York, New YorkNYU Langone Health
Feb 7, 2022
Carcinoma, Squamous Cell Trial in Pittsburgh (5-fluorouracil, Imiquimod 5% cream)
Recruiting
- Carcinoma, Squamous Cell
- 5-fluorouracil
- Imiquimod 5% cream
-
Pittsburgh, PennsylvaniaSt. Margaret Hospital Dermatology
Sep 12, 2021
Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma
Recruiting
- Stage III Hepatocellular Carcinoma AJCC v8
- +6 more
- Fluorouracil
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Nov 18, 2021
Cervical Intraepithelial Neoplasia Grade 2/3, Cervical Squamous Cell Carcinoma In Situ, Cervical Squamous Intraepithelial
Active, not recruiting
- Cervical Intraepithelial Neoplasia Grade 2/3
- +3 more
- Imiquimod
- Topical Fluorouracil
-
Chapel Hill, North CarolinaUNC Lineberger Comprehensive Cancer Center
Jan 28, 2022
Recurrent Rectal Cancer, Stage IIA Rectal Cancer, Stage IIB Rectal Cancer Trial in United States (trametinib, fluorouracil,
Active, not recruiting
- Recurrent Rectal Cancer
- +6 more
- trametinib
- +2 more
-
Saint Louis, Missouri
- +3 more
Feb 15, 2022
Colon Cancer, Rectal Cancer, Chemo Effect Trial in Beijing (5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil
Recruiting
- Colon Cancer
- +4 more
- 5-fluorouracil + formyltetrahydrofolate/Oxaliplatin + 5-fluorouracil + formyltetrahydrofolate/Irinotecan + 5-fluorouracil + formyltetrahydrofolate/Cetuximab + 5-fluorouracil + formyltetrahydrofolate
-
Beijing, Beijing, ChinaPeking Union Medical College Hospital
Jun 15, 2022
Pancreatic Ductal Adenocarcinoma Trial in United States (Onvansertib, Nanoliposomal irinotecan, Leucovorin)
Recruiting
- Pancreatic Ductal Adenocarcinoma
- Onvansertib
- +3 more
-
Phoenix, Arizona
- +5 more
Jun 16, 2022
Plantar Wart Trial in Sohag (Bleomycin and 5-fluorouracil)
Not yet recruiting
- Plantar Wart
- Bleomycin and 5-fluorouracil
-
Sohag, EgyptSohag Faculty of Medicine
Sep 26, 2021
Advanced Biliary Tract Cancer Trial in Washington, Indianapolis, Saint Louis (Nanoliposomal Irinotecan, Leucovorin,
Recruiting
- Advanced Biliary Tract Cancer
- Nanoliposomal Irinotecan
- +2 more
-
Washington, District of Columbia
- +2 more
Oct 29, 2021
Head and Neck Squamous Cell Carcinoma Trial (pembrolizumab+cisplatin + 5-fluorouracil)
Not yet recruiting
- Head and Neck Squamous Cell Carcinoma
- pembrolizumab+cisplatin + 5-fluorouracil
- (no location specified)
Jun 30, 2022
Warts Flat Trial in Zagazig (Tazarotene 0.1% Gel,Top, Imiquimod, Fluorouracil Cream)
Recruiting
- Warts Flat
- Tazarotene 0.1% Gel,Top
- +3 more
-
Zagazig, Select Region, EgyptDermatology department, Zagazig University Hospitals, Faculty of
May 12, 2022
Colorectal Cancer Trial in Philadelphia (Regorafenib, 5-FU, Leucovorin)
Terminated
- Colorectal Cancer
- Regorafenib
- +2 more
-
Philadelphia, PennsylvaniaFox Chase Cancer Center
Jan 10, 2022
Keloid, Keloid Scar Following Surgery Trial in Baton Rouge (Triamcinolone Injection, Triamcinolone Injection and 5-fluorouracil
Recruiting
- Keloid
- Keloid Scar Following Surgery
- Triamcinolone Injection
- Triamcinolone Injection and 5-fluorouracil injection
-
Baton Rouge, LouisianaOur Lady of the Lake Hospital
Sep 8, 2021
Hepatocellular Carcinoma Trial in Foshan, Guangzhou (HAIC, FOLFOX 2d, FOLFOX 1d)
Recruiting
- Hepatocellular Carcinoma
- HAIC
- +2 more
-
Foshan, Guangdong, China
- +2 more
Jul 26, 2022
Gastric Adenocarcinoma Trial (Pembrolizumab, Cisplatin, 5-FU)
Completed
- Gastric Adenocarcinoma
- Pembrolizumab
- +4 more
- (no location specified)
Aug 18, 2022